Venetoclax directly inhibits BCL-2 (BH3 mimetic), releasing pro-apoptotic factors to activate BAX/BAK, trigger mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-mediated apoptosis in BCL-2–dependent cells.